Time to Initiate Anti-vascular Endothelial Growth Factor Therapy and Visual Outcome in Central Retinal Vein Occlusion

Overview

Journal Sci Rep

Specialty Science

Date 2024 Jul 23

PMID 39043891

Authors

Chisato Agata

Shuichiro Aoki

Kohdai Kitamoto

Keiko Azuma

Ryosuke Fujino

Tatsuya Inoue

Ryo Obata

Affiliations

Soon will be listed here.

Abstract

This retrospective study aimed to investigate the progression of central retinal vein occlusion (CVO) prior to treatment initiation and its impact on prognosis. Of the 54 studied eyes with acute CVO, the average logMAR visual acuity (VA) at the initial visit was 0.65 ± 0.49 with an average time to treatment of 14.9 ± 14.5 days. VA at the initial treatment was identified as a stronger predictor of VA at the final visit compared to VA at the first visit or other factors. Patients who received treatment more than 28 days after the initial visit experienced a significant decline in VA compared to those treated within 28 days (0.21 ± 0.35 vs. 0.04 ± 0.13, p = 0.006). Additionally, patients who were treated between 15 and 28 days showed a greater decrease in VA compared to those treated within 14 days (0.12 ± 0.46 vs. 0.018 ± 0.02, p = 0.026). These findings from the current retrospective analysis suggesting that there is a possibility of VA decline at the initial treatment associating with worse prognosis even when treatment is administered within a month should be further investigated in the prospective study. Also, it may be crucial to consider frequent monitoring of acute CVO patients for initiating treatment at the optimal timing.

References

Brown D, Campochiaro P, Singh R, Li Z, Gray S, Saroj N . Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010; 117(6):1124-1133.e1. DOI: 10.1016/j.ophtha.2010.02.022. View

Nicholson L, Talks S, Amoaku W, Talks K, Sivaprasad S . Retinal vein occlusion (RVO) guideline: executive summary. Eye (Lond). 2022; 36(5):909-912. PMC: 9046155. DOI: 10.1038/s41433-022-02007-4. View

Lee D, Lee S, Yoon I . Clinical progress in impending central retinal vein occlusion. Korean J Ophthalmol. 2010; 24(2):83-8. PMC: 2851007. DOI: 10.3341/kjo.2010.24.2.83. View

Dewan K, Hentati F, Greenlee T, Conti T, Chen A, Hom G . Age-related differences in presentation and outcomes of anti-VEGF treatment of retinal vein occlusion. Can J Ophthalmol. 2020; 56(2):96-104. DOI: 10.1016/j.jcjo.2020.09.004. View

Brown D, Heier J, Clark W, Boyer D, Vitti R, Berliner A . Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol. 2012; 155(3):429-437.e7. DOI: 10.1016/j.ajo.2012.09.026. View

Sen P, Gurudas S, Ramu J, Patrao N, Chandra S, Rasheed R . Predictors of Visual Acuity Outcomes after Anti-Vascular Endothelial Growth Factor Treatment for Macular Edema Secondary to Central Retinal Vein Occlusion. Ophthalmol Retina. 2021; 5(11):1115-1124. PMC: 8565966. DOI: 10.1016/j.oret.2021.02.008. View

Azuma K, Tan X, Asano S, Shimizu K, Ogawa A, Inoue T . The association of choroidal structure and its response to anti-VEGF treatment with the short-time outcome in pachychoroid neovasculopathy. PLoS One. 2019; 14(2):e0212055. PMC: 6375588. DOI: 10.1371/journal.pone.0212055. View

Daien V, Navarre S, Fesler P, Vergely L, Villain M, Schneider C . Visual acuity outcome and predictive factors after bevacizumab for central retinal vein occlusion. Eur J Ophthalmol. 2012; 22(6):1013-8. DOI: 10.5301/ejo.5000162. View

Campochiaro P, Heier J, Feiner L, Gray S, Saroj N, Rundle A . Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010; 117(6):1102-1112.e1. DOI: 10.1016/j.ophtha.2010.02.021. View

10.

Light J, Tian J, Wenick A . Outcomes in Retinal Vein Occlusions Presenting with Poor Visual Acuity Treated with Anti-Vascular Endothelial Growth Factor Therapy: Prognosis and Predictive Factors. Ophthalmol Retina. 2020; 5(9):888-900. DOI: 10.1016/j.oret.2020.11.010. View

11.

Song P, Xu Y, Zha M, Zhang Y, Rudan I . Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, incidence, and risk factors. J Glob Health. 2019; 9(1):010427. PMC: 6513508. DOI: 10.7189/jogh.09.010427. View

12.

Holz F, Roider J, Ogura Y, Korobelnik J, Simader C, Groetzbach G . VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. Br J Ophthalmol. 2013; 97(3):278-84. DOI: 10.1136/bjophthalmol-2012-301504. View

13.

Larsen M, Waldstein S, Boscia F, Gerding H, Mones J, Tadayoni R . Individualized Ranibizumab Regimen Driven by Stabilization Criteria for Central Retinal Vein Occlusion: Twelve-Month Results of the CRYSTAL Study. Ophthalmology. 2016; 123(5):1101-11. DOI: 10.1016/j.ophtha.2016.01.011. View

14.

Yoon Y, Kim H, Yoon H, Kang S, Kim J, Park K . Improved visual outcome with early treatment in macular edema secondary to retinal vein occlusions: 6-month results of a Korean RVO study. Jpn J Ophthalmol. 2014; 58(2):146-54. DOI: 10.1007/s10384-014-0305-9. View

15.

Yasuda M, Kiyohara Y, Arakawa S, Hata Y, Yonemoto K, Doi Y . Prevalence and systemic risk factors for retinal vein occlusion in a general Japanese population: the Hisayama study. Invest Ophthalmol Vis Sci. 2010; 51(6):3205-9. DOI: 10.1167/iovs.09-4453. View